PLUR Stock Overview A biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Pluri Historical stock prices Current Share Price US$16.76 52 Week High US$29.99 52 Week Low US$15.35 Beta 1.63 1 Month Change -9.16% 3 Month Change -17.56% 1 Year Change 2.05% 3 Year Change -65.43% 5 Year Change -84.76% Change since IPO -97.70%
Recent News & Updates
High number of new and inexperienced directors Dec 08
Pluri Receives Nasdaq Notification of Non-Compliance with Listing Rule 5550(B)(1) Nov 28
Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement Jul 24 Pluri Inc. Announces Executive Changes, Effective September 30, 2024
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract Jun 08
Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Jun 01 See more updates
High number of new and inexperienced directors Dec 08
Pluri Receives Nasdaq Notification of Non-Compliance with Listing Rule 5550(B)(1) Nov 28
Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement Jul 24 Pluri Inc. Announces Executive Changes, Effective September 30, 2024
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract Jun 08
Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Jun 01 Pluri Inc., Annual General Meeting, Jun 25, 2024
New minor risk - Shareholder dilution Apr 02
Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation Mar 11
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board Mar 06 Pluri Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Feb 14
Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023) Feb 13
New minor risk - Share price stability Jan 24
Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis Jan 23
Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division Jan 08
First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 1Q 2023) Nov 15
Pluri Receives an Extension of an Additional 180 Calendar Days from The Nasdaq Stock Market LLC to Regain Compliance with the Minimum Bid Price Requirement Oct 20
Full year 2023 earnings released: US$0.77 loss per share (vs US$1.28 loss in FY 2022) Sep 13
Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation Aug 17 Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors Jul 13
Pluri Inc. announced that it has received $8.469323 million in funding Dec 31
Pluri Inc. announced that it expects to receive $8.170972 million in funding Dec 16
High number of new and inexperienced directors Nov 16
Pluri Receives Non-Compliance Letter from Nasdaq Oct 14
Pluri Inc. Announces €7.5 Million Non-Dilutive Grant from the European Union’s Horizon Europe Program to Study PLX-PAD Cells for Osteoarthritis Treatment Sep 07
Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery Jul 14
Pluristem Therapeutics Inc. Announces Board Changes Jun 25
High number of new directors Apr 27
High number of new directors Apr 01 Pluristem Therapeutics Inc. and Tnuva Group Appoint Eyal Rosenthal as Chief Executive Officer of Their New Joint Venture Mar 10
High number of new directors Mar 02
Chairman recently bought ₪467k worth of stock Feb 18
Pluristem Therapeutics Inc. Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19 Dec 28
Independent Director Isaac Braun has left the company Jun 09
Insider recently sold ₪5.1m worth of stock May 28
Insider recently sold ₪330k worth of stock May 05
Pluristem Reports Positive Topline Phase I Results in Innovative Hematology Program, Which Is First to Study PLX-R18 in humans Apr 30
New 90-day low: ₪17.40 Mar 04
Revenue in line with expectations Feb 10
Pluristem Therapeutics Inc. Announces Board Appointments Jan 08
Pluristem Therapeutics Inc. Enters Collaboration With Innovare R&D to Expand Its ARDS Associated With COVID-19 Program to Mexico Dec 30
Pluristem Therapeutics Inc. Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study Dec 11
New 90-day low: ₪24.00 Dec 09
Insider recently bought ₪641k worth of stock Dec 02
Pluristem Therapeutics Inc. to Present Initial Results from its Phase I HCT Study Nov 19
New 90-day low: ₪28.82 Nov 11
Revenue in line with expectations Nov 07
Insider recently bought ₪629k worth of stock Oct 30
Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study Oct 14
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel Oct 07
Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects At Malta Conferences Foundation Online Event Oct 03
Insider recently bought ₪1.1m worth of stock Sep 27
Full year earnings released - ₪1.60 loss per share Sep 12
New 90-day high - ₪36.37 Aug 28 Shareholder Returns PLUR IL Biotechs IL Market 7D -4.7% -0.6% -0.5% 1Y 2.0% -24.8% 23.0%
See full shareholder returns
Return vs Industry: PLUR exceeded the IL Biotechs industry which returned -24.8% over the past year.
Return vs Market: PLUR underperformed the IL Market which returned 23% over the past year.
Price Volatility Is PLUR's price volatile compared to industry and market? PLUR volatility PLUR Average Weekly Movement 10.1% Biotechs Industry Average Movement 4.9% Market Average Movement 4.2% 10% most volatile stocks in IL Market 8.0% 10% least volatile stocks in IL Market 3.0%
Stable Share Price: PLUR's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: PLUR's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform. The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform.
Show more Pluri Inc. Fundamentals Summary How do Pluri's earnings and revenue compare to its market cap? PLUR fundamental statistics Market cap ₪89.02m Earnings (TTM ) -₪79.38m Revenue (TTM ) ₪2.18m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PLUR income statement (TTM ) Revenue US$598.00k Cost of Revenue US$130.00k Gross Profit US$468.00k Other Expenses US$22.28m Earnings -US$21.81m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.92 Gross Margin 78.26% Net Profit Margin -3,646.99% Debt/Equity Ratio -40,261.9%
How did PLUR perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 19:20 End of Day Share Price 2024/12/19 00:00 Earnings 2024/09/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Pluri Inc. is covered by 17 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners George Zavoico B. Riley Securities, Inc. Jason Kolbert B. Riley Wealth
Show 14 more analysts 
